medRxiv preprint doi: https://doi.org/10.1101/2024.09.05.24313105; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Safety and tolerability of intravenous liposomal **GM1** in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)

Stefan Halbherr¹, Stefanie Lerch^{1,2}, Sebastian Bellwald³, Petra Polakova^{1,4}, Bettina Bannert⁵, Marie 1 Roumet⁶, Roch-Philippe Charles^{1,7}, Martin A. Walter⁸, Corrado Bernasconi⁹, Camille Peitsch¹, Pascal C. 2 Baumgartner¹, Céline Kaufmann¹, Heinrich P. Mattle¹⁰, Alain Kaelin-Lang¹¹, Andreas Hartmann¹², 3 Michael Schuepbach^{3*} 4

5

11

12

13 14

15

16

- 1 InnoMedica Schweiz AG, Switzerland
- 2 Skin and Soft Tissue Research Center, University Children's Hospital Zurich, Switzerland
- Institute of Neurology, Konolfingen, Switzerland 3
- 4 Swiss pediatric oncology group, Bern, Switzerland
- 5 Department of Clinical Research, University of Basel, Switzerland
- 6 Department of Clinical Research, University of Bern, Switzerland
- 7 Swiss Group for Clinical Cancer Research, Switzerland8 St. Anna Hospital, University of Lucerne, Switzerland
- 9 Limites Medical Research Ltd., Vacallo, Switzerland ORCID 0000-0002-1019-5468
- 10 University of Bern, Switzerland, ORCID 0000-0001-7968-1731
- 11 Ente Ospedaliero Cantonale, Lugano Switzerland
- 12 Assistance-Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Neurologie, Paris, France
- 17 18

19 Revision date: 16.08.2024

- 20 Revised word count: 6288
- 21 *corresponding Author
- 22 E-mail: nik@hin.ch
- 23 Participating Center: Institute of Neurology, Konolfingen, Switzerland
- Safety re-assessment: Clinical Trial Unit, Department of Clinical Research, University of Basel 24
- 25 Database programming & Statistical Analysis: Clinical Trial Unit, University of Bern
- Data and Safety Monitoring Board (DSMB): Andreas Hartmann, Alain Kaelin-Lang, Heinrich Mattle NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 26
- 27 Data access and responsibility: InnoMedica Schweiz AG

28 ABSTRACT

29 Background:

30 Parkinson disease (PD) is a chronic progressive neurodegenerative disorder leading to motor and non-31 motor impairment often resulting in severe loss of quality of life. There are symptomatic treatments 32 without effect on the progression of PD. A disease-modifying treatment that could ideally stop the 33 neurodegenerative process is direly needed. Monosialotetrahexosylganglioside (GM1) is a promising molecule with neuroprotective effects in preclinical models of PD and has yielded encouraging results 34 35 in patients with PD in a randomized placebo-controlled trial. Talineuren (TLN) is a liposomal 36 formulation of GM1 that has been shown to cross the blood-brain barrier in animals. We assessed the 37 safety and pharmacokinetics of TLN in patients with PD.

38 Methods and Findings

39 We prospectively enrolled 12 patients with PD into a single-center, open-label phase I trial to assess 40 the safety and tolerability of weekly infusions with Talineuren. The maximum suitable dose of 41 Talineuren was determined by dose escalation in three patients. Subsequently, these and nine further 42 patients received weekly infusions at the maximum suitable dose of Talineuren over two months (1 43 patient stopped prematurely). All adverse events were continuously assessed as the primary objective 44 and coded according to the Medical Dictionary for Regulatory Activities (MedDRA®). Clinical 45 manifestations of PD were assessed as secondary outcomes using the Movement Disorders Society 46 Unified Parkinson's Disease Rating Scale (MDS-UPDRS) including a levodopa challenge test at baseline 47 and end. In addition to weekly history taking, scales to measure mood, behaviour, guality of life, 48 sleepiness, non-motor symptoms of PD, and cognition were used. Dose escalation identified a 49 maximum suitable weekly dose of 720 mg. Overall, 304, mostly mild adverse events occurred. Twentythree were considered related to the study treatment. Very mild to severe acute infusion reactions at 50 the 2nd, 3rd, or 4th administration of TLN within the first minutes of the infusion occurred in seven 51 52 patients. All reported back or neck pain. Other acute infusion reactions were urticaria, plethora,

53 nausea, and chest pain. These adverse reactions disappeared within minutes of stopping the infusion 54 and did not recur when Talineuren administration was resumed at a very low rate. Beyond the 4th 55 administration, infusions could be given at increased rates up to 370 ml/h and no acute reaction 56 occurred anymore. The mechanism of this acute infusion reaction remains unclear. Some patients 57 reported mild dizziness for a few hours after Talineuren following many but not all administrations 58 throughout the study. Non-motor symptoms of PD, motor parkinsonian signs off medication, and 59 quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease 11.09±10.47 points; p=0.006) and the PDQ-39 summary index (mean decrease 60 61 2.91 ± 2.25 points, p =0.002). Dopaminergic medications remained stable during the study.

62 Conclusion:

Talineuren is safe and well-tolerated in general. This prospective phase I trial revealed non-allergic
habituating acute infusion reactions at the 2nd, 3rd, or 4th treatment that can be prevented by a
slower rate of infusion. Importantly, the exploratory results suggest a consistent improvement of signs
and symptoms of PD.
Abstract word count: 487

Trial Registration: The NEON trial is registered at the US National Institutes of Health
(ClinicalTrials.gov) #NCT04976127 and in the Swiss National Clinical Trials Portal (SNCTP000004631)
Funding: NEON was fully funded by InnoMedica Switzerland AG.

71 Introduction

72 Parkinson disease (PD) is a chronic progressive neurodegenerative disorder with motor signs and non-73 motor symptoms. Its clinical hallmark is Parkinsonism, i.e., bradykinesia associated with rest tremor 74 or rigidity (1). Although the motor signs remain the primary defining feature of PD, vegetative, 75 behavioural, and cognitive symptoms may have a predominant effect on quality of life, and often 76 precede motor signs (2). Histologically, PD is characterized by alpha-synuclein containing neuronal 77 inclusions called Lewy bodies that propagate through the brain resulting in impaired function of 78 numerous systems (3,4). Some manifestations of PD can symptomatically be relieved with medication 79 or stereotactic procedures, but despite considerable ongoing research efforts (5), there is currently 80 no known disease-modifying treatment available for PD. The most important therapeutic potential 81 currently consists of medications for the substitution of dopamine loss due to degeneration of 82 dopaminergic neurons in the substantia nigra. However, over decades of disease progression 83 levodopa-resistant symptoms become the main cause for disability. A treatment to slow down or even 84 halt the pathological process in PD is direly needed.

85 The glycosphingolipid GM1 (monosialotetrahexosylganglioside) is an important component of the cell 86 membrane of neurons that is diminished in patients with PD (6). GM1 has shown neurotrophic and 87 neuroprotective properties in preclinical research (7), and decreased levels of GM1 in patients with 88 PD may contribute to the pathogenesis (8). Studies in animal models of PD have shown recovery with 89 GM1 treatment (9), and a randomized double-blinded placebo-controlled clinical study in 77 patients 90 treated with twice daily subcutaneous administration of 100 mg GM1 resulted in a significant benefit compared to placebo over 120 weeks (10) Administration and therapeutic effects of GM1 may be 91 92 improved by using a neurotropic nanoparticle carrier. Talineuren (TLN) is a liposomal formulation 93 consisting of the active pharmaceutical ingredient (API) GM1 at 6 mg/ml and the carrier liposomes 94 consisting of sphingomyelin and cholesterol. We conducted a phase I safety trial in 12 PD patients receiving weekly TLN infusions over 8 weeks minimum. 95

96 Methods

97 Study Design

98 In this single-centre, open-label phase I interventional trial we enrolled 12 patients with PD to assess the safety, tolerability, and preliminary efficacy of liposomal GM1 as add-on medication with weekly 99 100 intravenous infusions. Three patients received weekly ascending doses for 14 weeks to establish the 101 highest well-tolerated dose (dose escalation group [DE]). The highest tested weekly dose of the API 102 was 720 mg based on previous use of GM1 in humans (11) and was reached in all three patients. DE 103 patients and 9 additional patients (dose consolidation group [DC]) received thereafter weekly TLN with 104 an API dose of 720 mg for 8 weeks between December 13, 2021 and June 20, 2022. One of these 105 patients stopped participation prematurely. One month after the last administration of TLN, a final 106 safety follow-up visit was performed. Antiparkinsonian medication was kept stable if possible. In two 107 patients with bilateral subthalamic nucleus stimulation, stimulation remained on and parameters 108 unchanged throughout the study.

109 An independent data safety monitoring board (DSMB) evaluated safety data when the 3 DE patients 110 had reached a GM1 dose of 180 mg and after completion of the dose escalation. The trial was approved by the local ethics committee (Kantonale Ethikkommission Bern) and the competent 111 authority October 30, 2021. The trial is registered at the US National Institute for Health 112 (ClinicalTrials.gov NCT04976127). The trial was conducted according to the principles of the 113 114 Declaration of Helsinki and Good Clinical Practice guidelines. Talineuren is provided by the 115 manufacturer and sponsor of the study, InnoMedica Switzerland AG. Talineuren is produced under GMP conditions at InnoMedica's Nanofactory in Marly (Freiburg, Switzerland). 116

117 **Patients**

Patients aged 40-80 years were eligible if they were diagnosed with PD according to British brain bank
criteria (12), had a Hoehn and Yahr Stage 0 – 2.5 on medication (13) and stable PD treatment for at
least 4 weeks. To exclude major cognitive deficits, a score >25 on the Montreal Cognitive Assessment

(14) was required. Patients were carefully selected to exclude medical, psychological, and behavioural
 problems that may have interfered with their compliance for study participation. Patients provided
 written informed consent and fulfilled all eligibility criteria.

124 **Dose escalation (DE)**

125 In patients 1-3 dose escalation was started at 6 mg GM1 and then increased weekly to 12 mg, 60 mg, 126 followed by increases of 60 mg/week up to 720 mg. TLN was provided as a concentrated liposomal 127 suspension containing cholesterol, sphingomyelin, and the active pharmaceutical ingredient GM1 in 128 30ml vials (180 mg GM1) in a phosphate buffered solution. Talineuren was diluted in phosphate 129 buffered saline with a final concentration of 6 mg/ml GM1. TLN was added to 250 ml NaCl 0.9% and 130 administered with 250 ml/h with a perfusor. The speed of infusion could be increased up to 370 ml/h 131 if tolerated but reduced if necessary. Three days after the infusion each weekly dose increase of the 132 TLN had to be cleared by an internal safety monitoring committee (MS, RPC, MW) by assessing clinical 133 symptoms and lab values (Appendix 1). The second and third patient could start with the lowest dose 134 with a delay of 1 week after confirmation of safety in the first patient. This 1+2 schedule was 135 maintained for each weekly increase to allow for modification of the increasing of doses if needed according to a predefined dose modification matrix. All 3 patients had two clinical and lab assessments 136 each week during the 14 weeks of the dose escalation phase. The average of the three maximal 137 138 tolerated doses was defined as maximal suitable dose (MSD) for the dose consolidation (DC) part of 139 the trial.

140 **Dose consolidation (DC)**

After DE, the initial 3 and additional 9 patients received weekly infusions of TLN with an API dose of 720 mg and clinical and lab safety assessments over 8 weeks except for one patient who stopped participation early. A final safety assessment was performed one month after the last administration of TLN.

145 **Pharmacokinetics**

Pharmacokinetic parameters were determined for GM1 from individual concentration time profiles obtained after the first intravenous infusion administration of 720 mg GM1 in the 9 DC patients. Blood samples were drawn before the infusion started and after the start of the infusion (250 ml/h, 370 ml total volume) at 5 minutes, 1 hour, 4, 8, 24, 48, 72, and 96 hours. Samples were immediately centrifuged and frozen at -70°C. GM1 concentration was measured using liquid chromatography with tandem mass spectrometry.

152 Noncompartmental pharmacokinetic analysis was performed using Phoenix WinNonlin version 8.0 153 [Pharsight Corporation, Mountain View, CA, USA] using the intravenous infusion dosing option. 154 Pharmacokinetic variables were estimated from the plasma concentration versus time curves: t_{max} 155 (time to reach the maximum plasma concentration read directly from the plasma concentration-time curve), C_{max} (maximum plasma concentration read directly from the plasma concentration-time 156 157 curve), AUC_{0-∞} (area under the plasma concentration-time curve from time point zero to infinity, 158 estimated from AUC_{0-t} + C_t/ λ_z , where t is the last sampling time with a concentration above the limit 159 of quantification and λ_z is the terminal elimination rate constant, estimated by log-linear least squares 160 regression of the plasma concentration versus time data in the terminal phase; AUC_{0-∞} was calculated 161 according to the linear trapezoidal with linear/log interpolation rule), t_{1/2}: (apparent terminal half-life 162 calculated as $ln2/\lambda_z$, CL: (apparent clearance calculated as dose divided by AUC_{0-∞}), V_z (apparent 163 volume of distribution calculated as dose divided by $\lambda_z * AUC_{0-\infty}$).

164 **Outcome measures**

The primary outcome was safety defined as the occurrence of adverse events. Safety assessments included a full medical history at baseline, a full general physical medical and neurological examination at baseline, a final assessment and last follow-up, and detailed unstructured interviews at each visit and if needed by phone. A narrative description of adverse events and their duration, intensity, seriousness, and relation to TLN were recorded by the site investigators. Adverse events were coded by an independent expert with the Medical Dictionary for Regulatory Activities (MedDRA®).

Adverse events were considered unrelated to TLN if a plausible other explanation for the observation was available. Otherwise, adverse events without plausible causal relation to TLN but lacking a different explanation were considered to be unlikely related to TLN. Safety data were weekly reviewed by an internal safety board (MS, RPC, MAW) during the dose escalation period. Any out-of-range laboratory result was counted as an adverse event.

176 Parkinsonian motor signs and non-motor symptoms were further explored weekly using the 177 Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (15) parts 1 (non-178 motor experiences of daily living), 2 (motor experiences of daily living), 3 (motor examination), and 4 179 (motor complications). The MDS-UPDRS-2 was assessed for best and worst condition in the preceding 180 week in patients with motor fluctuations. The MDS-UPDRS-3 was assessed before and after each administration of TLN and also at baseline and final assessment in a levodopa challenge test (LCT). For 181 182 the LCT patients paused their dopaminergic medications for at least 12 hours before the assessment 183 "off" medication. The usual morning dose of levodopa equivalence plus 50 mg levodopa was then 184 given as liquid formulation of levodopa/benserazide (in 1 patient levodopa/carbidopa) for the ensuing 185 assessment "on" medication. Levodopa equivalent daily doses were noted weekly and calculated 186 according to standard procedures (16). The number of PD-related non-motor symptoms was assessed 187 with the Non-Motor Symptoms Questionnaire (NMSQuest) (17) at baseline and weekly during the 188 course of the trial. Questionnaires at baseline and final assessment included the Parkinson's disease 189 Questionnaire-39 (PDQ-39) (18) for disease-related quality of life, the Epworth Sleepiness Scale (19), the Montreal Cognitive Assessment (MoCA (20) for mental performance, the Beck Depression 190 191 Inventory (BDI) (21) to assess mood, and the Starkstein Apathy Scale (22).

192 Statistical analysis

After completion of data entry, data validation and cleaning were performed. Data analysis was started. All patients enrolled in this study received at least one dose of study medication and were considered in the safety and tolerability analysis.

PK analysis plasma concentrations and PK parameters were analyzed for the 9 patients of the consolidation group and reported in a descriptive fashion. Descriptive statistics include arithmetic mean, SD, minimum, median, maximum, geometric mean, and coefficient of variation of arithmetic and geometric means.

200

201 Other study outcomes including scores measuring the Parkinsonian motor signs and non-motor 202 symptoms, disease related quality of life, levodopa equivalent daily dose, and mental performance 203 were assessed in the 11 patients who received at least two full-dose infusions and completed at least 204 the MDS-UPDRS at these two visits. For patients included in the escalation part we used as baseline 205 value the values assessed at the start of the trial (i.e. before the start of the escalation part). 206 We used summary statistics to describe the outcomes values at baseline, after 8 weeks of treatment, 207 and the observed changes. For each outcome, the significance of the change from baseline was 208 assessed using a paired Wilcoxon signed-rank test. No correction for multiplicity was applied. 209 Few outcomes including the blood lab values of cholesterol (total, LDL, HDL, ratio total/HDL), triglycerides, and apolipoprotein B were defined, post-hoc, as additional outcomes. For these 210 211 outcomes, we used summary statistics to describe the weekly assessed values. At each time point, the

significance of the change from baseline was assessed using a paired Wilcoxon signed-rank test.

perpetuity. It is made available under a CC-BY 4.0 International license .



213



215 **Results**

216 **Trial population**

217 There were no screening failures. Twelve patients (including three women) were recruited. At

218 inclusion the median age was 65 (range 46-75) years old and had had motor parkinsonian signs for

- 219 7.9±5.2 (range 2-19, median 6.5) years. Three patients had only akinetic-rigid signs and nine patients
- also rest tremor. All patients had been clinically diagnosed with PD. For the patient characteristics see
- 221 Table 1.

222 Table 1. Patient characteristics.

Characteristic	Overall, N = 12	Dose consolidation , N = 9	Dose escalation, N = 3
Age at registration (years)		1	
Median (range)	65.0 (46.0–75.0)	65.0 (51.0–75.0)	63.0 (46.0–68.0)
Sex - Female, n (%)	3 (25%)	2 (22%)	1 (33%)
Height (cm)		1	
Median (range)	172.0 (159.0–183.0)	172.0 (160.0–183.0)	174.0 (159.0–182.0)
Weight (kg)			
in	78.5 (60.0–99.0)	78.0 (64.0–99.0)	88.0 (60.0–99.0)
BMI (kg/m ²)		1	
Median (range)	26.2 (21.6–32.7)	25.8 (21.6–30.8)	26.6 (23.7–32.7)
Hoehn and Yahr stage at s	creening, n (%)	1	
Stage 0 (no signs of disease)	0 (0%)	0 (0%)	0 (0%)
Stage 1 (unilateral involvement only)	3 (25%)	2 (22%)	1 (33%)
Stage 1.5 (unilateral and axial involvement)	5 (42%)	4 (44%)	1 (33%)
Stage 2 (Bilateral involvement without impairment of balance)	4 (33%)	3 (33%)	1 (33%)
Stage 2.5 (Mild bilateral disease with recovery on pull test)	0 (0%)	0 (0%)	0 (0%)
Drugs		l	
L-DOPA, n (%)	12 (100%)	9 (100%)	3 (100%)
Non-ergot-derived dopamine receptor agonist, n (%)	8 (67%)	6 (67%)	2 (67%)
MAO-B Inhibitor, n (%)	4 (33%)	3 (33%)	1 (33%)
COMT inhibitor, n (%)	3 (25%)	3 (33%)	0 (0%)
NMDA agonist, n (%)	1 (8.3%)	1 (11%)	0 (0%)
Other, n (%)	1 (8.3%)	1 (11%)	0 (0%)
LEDD (mg)			1
Median (range)	650.0 (340.0–1,275.0)	750.0 (340.0–1,275.0)	550.0 (375.0–1,010.0)

224 Safety

225 Dose escalation

226 Weekly dose escalation of TLN from 6 to 720 mg GM1 i.v. at a rate of 250 ml/h was well tolerated 227 without major adverse effects. Mild neck and lumbar pain occurred for 15 minutes in one patient 228 during the second (12 mg) and reappeared very mildly for a few minutes during the third (60 mg) 229 infusion with TLN. Otherwise, dose escalation was unremarkable for all three patients and reached 230 720 mg with good tolerance. One patient reported transient beneficial effects of TLN treatment on sleep, mood, and general energy levels during dose escalation lasting longer with increasing doses. At 231 232 the end of the dose escalation, the subjective beneficial effects of the weekly infusions lasted almost 233 a week in this patient.

234

235 Pharmacokinetics

After first intravenous application of TLN with an API dose of 720 mg, repeated blood sampling showed the plasma peak of TLN in the sample taken 4 hours after start of the infusion in all but one patient in whom the peak was reached at 1 hour after start of the infusion. This patient was the patient who had the severe acute infusion reaction at the second administration. Pharmacokinetic variables are given in Table 2.

241 Table 2. Pharmacokinetic variables for GM1 after i.v. infusion administration of 720 mg GM1 in the

n=0	C _{BL}	C _{max}	t ½	AUC₀.∞	Vz	CL
n=9	(ng/ml)	(ug/ml)	(h)	(h*ug/ml)	(ml)	(ml/h)
Mean	52.8	212	15.0	5'011	4'188	210
SD	30.8	153	6.48	4'035	2'666	113
Minimum	0	84	10.2	1'920	2'020	49
Median	65.4	147	12.6	3'860	3'290	187
Maximum	84.5	582	30.7	14'700	10'000	375

dose consolidation patients group (n = 9). 242

 C_{BL} : baseline plasma concentration before TLN administration. C_{max} : maximum plasma concentration 243

read directly from the plasma concentration-time curve. t_{χ} : apparent terminal half-life. AUC_{0- ∞}: area 244

under the plasma concentration-time curve from time point zero to infinity. Vz: apparent volume of 245

246 distribution. CL: apparent clearance.





248 Fig 2. Mean (±SD) GM1 plasma concentration-time profiles after intravenous infusion

249 administration of 720 mg GM1 (linear).

250 Dose consolidation

During the dose consolidation phase, acute infusion reactions occurred in 6 patients shortly after the start of the 2nd (6 patients), 3rd (1 patient), and 4th (1 patient) administration of TLN (see below). One patient with a severe infusion reaction did not receive any further TLN treatment. During all following treatments with TLN, no acute infusion reactions occurred. The maximum dose of GM1 720 mg/week could be maintained throughout the study.

256 Adverse events

Overall, 304, mostly mild adverse events occurred. No serious adverse event was reported in this study. Twenty-three adverse events were affirmatively related to the study treatment. The causal relation to the study treatment was considered probable in 17 (all mild), possible in 100, and unlikely in 123 observations. Forty-one adverse events were unrelated to the study treatment.

261



262

Fig 3. Observed adverse events (n = 304) during dose escalation and dose consolidation with Talineuren.

265 Adverse events definitively or probably related to TLN can be separated into a group of immediate 266 mild to severe infusion reactions that abated after halting the administration of TLN (see below), and 267 a group of more diffuse, always mild reactions often occurring with some hours' delay after the TLN 268 infusion. The latter group comprises mild tension headache (n=3), nausea (n=1), and arterial 269 hypertension during emotional tension (n=1) during the infusion, and dizziness (n=6), inner tension 270 and tremulousness (n=2), and tension headache (n=4) occurring within hours after the infusion, 271 spontaneously remitting within less than a day. One patient suffered from mildly depressed mood 272 during the withdrawal of TLN after the dose escalation phase, partly because he missed the beneficial 273 effects of the weekly infusions. This symptom remitted spontaneously before TLN was resumed in the 274 consolidation phase of the study.

Acute infusion reactions occurred in one patient during dose escalation (2nd and 3rd administration), 275 and in six patients during dose consolidation, always within minutes of the 2nd administration of TLN. 276 In two patients, an acute infusion reaction was observed at the 3rd administration, in one very mildly 277 during the 4th administration. Symptoms occurred after as little as 3 mg of liposomal GM1 was 278 279 administered and as early as within 1 minute after start of the infusion. Symptoms built up at variable 280 speeds and with mild to severe intensity among different patients. All symptoms abated within 281 minutes after stopping the infusion. Infusion could then be resumed at a low speed (10 ml/h) without recurrence of symptoms. In most cases, infusion speed could be increased swiftly up to the planned 282 250 ml/h except in one patient who required several hours for the 2nd infusion. However, later the 283 284 patient tolerated administrations of TLN at 250 ml/h without any adverse events. In one patient, the acute infusion reaction at the beginning of the 2nd administration quickly led to severe back, neck, and 285 286 chest pain. According to the study protocol, the patient had to be removed from the study and could 287 not be re-exposed at a lower infusion rate despite the patients' explicit request to continue study 288 participation. The acute infusion reactions (Table 3) included lower back, neck, and chest pain as the 289 most common symptom; lower back pain was present in all patients with an acute infusion reaction. 290 Lower back pain was very mild in two patients during three administrations and did not require the

infusion to be halted. One patient had itching during 2nd, 3rd, and 4th administration of TLN, and 291 urticaria on the trunk and the thighs (Table 3) during the 3rd infusion. Tryptase was normal before start 292 293 of TLN and within 30 minutes of the appearance of urticaria. Clemastine 2 mg was given i.v. and TLN 294 could be resumed without worsening of symptoms. Urticaria disappeared within a day and did not 295 recur during the following administrations of TLN. After the last occurrence of an acute infusion 296 reaction, patients received 19 (n=1, dose escalation), 6 (n=4), and 4 (n=1) infusions without 297 experiencing an acute infusion reaction. One patient was withdrawn from the study (Figure 1). In the 298 remaining 5 patients overall 68 TLN infusions were given without an acute infusion reaction.

Table 3. The number of patients with acute infusion reaction and the presented symptoms early

300 during the infusion.

Acute infusion reaction	2nd	3rd	4th
	administration	administration	administration
lower back pain	7*	2*	1
neck pain	2*	1*	0
itching, urticaria	1	1	1
nausea, chest pain	2	0	0
hypotension	1	0	0
thoracic congestion, plethora	1	0	0
eye flickering	1	0	0

- 301 The number of patients presenting with acute symptoms early during the infusion is given.
- *one patient from the dose escalation group, all others are from the dose consolidation group.

Adverse events possibly related to TLN (Table 4) comprised 46 mild out of normal range measures of cholesterol, triglycerides, or apolipoprotein B. These observations were considered possibly related to TLN because the study drug contains cholesterol and sphingomyelin. However, lipid assessments were performed in a non-fasting state for which no ranges of normality were available. The lipid levels of all study participants were fluctuating over the study period but did not consistently change except

308 for HDL cholesterol that was slightly but significantly reduced on all visits compared to baseline (see 309 Appendix 2). In one patient, one observation of a slightly elevated level of anti-GM1 IgM antibodies 310 was clinically asymptomatic and followed by normal levels in consecutive assessments. Many adverse 311 events possibly related to TLN could also be explained as motor (e.g. muscle cramps, tremor, 312 dysarthria, dysphagia) or non-motor (e.g., fatigue, sleep disorders, constipation, dysphoria) signs and symptoms of PD. During the four weeks pause after the dose escalation phase, one patient reported 313 314 25 adverse events of worsening parkinsonian motor and non-motor problems beyond baseline level. 315 This rebound remitted spontaneously to baseline for all reported aspects before TLN was resumed in 316 the dose consolidation phase. Mild tension headache, dizziness, nausea, and neck and lumbar pain

317 were noted as possible infusion reaction symptoms.

210	Table / Advance offerse		أمييتهم مطلق مقالم مقما مس		1
318	Table 4. Adverse effects l	DOSSIDIV	related to the stud	v treatment	n = 1001.
		p 0 0 0		y	(00/).

			Preferred terms of
Category of adverse events	n	System organ class terms	grade 2 adverse
			events
Abnormal blood lipids	46	Investigations	
Elevated anti-GM1-IgM	1	Investigations	
antibodies			
		Nervous system disorders. Psychiatric	
Neurologic and psychiatric	25	disorders. Eye disorders. Renal and	
events	25	urinary disorders. Reproductive system	
		and breast disorders	
Gastrointestinal disorders	7	Gastrointestinal disorders	nausea
Asthenia and fatigue	5	General disorders and administration site	fatigue
		conditions	
Possible infusion reactions	7	Injury, poisoning and procedural	procedural dizziness

		complications	
Musculoskeletal problems	8	Musculoskeletal and connective tissue disorders	muscle spasms
Skin disorders	1	Skin and subcutaneous tissue disorders	

319

320 System organ class terms and preferred terms were used according to the MedDRA coding system for

321 adverse effects.

322 Adverse events unlikely related to TLN (table 4) comprised mainly lab results mildly outside of the normal range. Two measures of hyperkalaemia (5.5 and 5.8 mmol/l) were clinically asymptomatic and 323 324 occurred without other lab abnormalities; an artefact due to erroneous sample handling was 325 assumed. A self-remitting episode of acute vestibular vertigo was the only severe adverse event 326 considered unlikely to be related to TLN.

327 Table 5. Adverse effects unlikely related to the study treatment (n=123).

Category of adverse events	n	System organ class terms	Preferred terms of grade 2 and 3 adverse events
Out of range laboratory findings	79	Blood and lymphatic system disorders. Investigations. Metabolism and nutrition disorders	increased blood potassium, pseudohyperkalemia
Ear, nose and labyrinth disorder	4	Ear and labyrinth disorders. Respiratory, thoracic and mediastinal disorders	acute vestibular syndrome
Gastrointestinal disorders	18	Gastrointestinal disorders	nausea, upper abdominal pain

perpetuity. It is made available under a CC-BY 4.0 International license .

Infections and infestations	2	Infections and infestations	post viral fatigue syndrome
Cardiovascular disorders	2	Cardiac disorders. Eye disorders	amaurosis fugax
Musculoskeletal and connective		Musculoskeletal and connective	hadunain
tissue disorders	9	tissue disorders	раск раш
Nervous system and psychiatric		Nervous system disorders.	
disorders	8	Psychiatric disorders	tension headache
Skin and subcutaneous tissue		Skin and subcutaneous tissue	
disorders		disorders	

328 System organ class terms and preferred terms were used according to the MedDRA coding system for

329 adverse effects.

Secondary outcome measures

At an early stage, 1 patient discontinued the study and was removed from the efficacy analysis, 331 meaning that the present analysis was performed on 11 patients. At the final assessment, 332 333 parkinsonian motor signs off medication improved 6.73±7.16 points (Pval = 0.01) on the MDS-UPDRS 334 3 assessed after 12 hours of withdrawal of dopaminergic medication (see Table 6). This corresponded 335 with the observation that pausing medication for the final assessment was much better tolerated than 336 at baseline. With medication (on state), no significant change in motor signs was found during the 337 study. TLN treatment did not result in a consistent and clinically relevant immediate beneficial effect 338 on parkinsonian motor signs (data not shown). Motor complications of dopaminergic treatment (MDS-339 UPDRS 4) did not change significantly during the study. There were fewer non-motor symptoms at 340 follow-up compared to baseline as assessed with the NMS-Quest (8.64 vs. 4.63, Pval = 0.009). Non-341 motor parkinsonian symptoms (MDS-UPDRS 1) and activities of daily living in the best condition (MDS-342 UPDRS 2 best) were significantly improved at follow-up compared to baseline (mean difference from 343 baseline -1.91, pval = 0.057 and -2.82, pval = 0.02; respectively).

The total MDS-UPDRS (including the MDS-UPDRS 2 in the worst condition and the MDS-UPDRS 3 off

345 medication) improved by 11.1±10.47 from baseline to follow-up (pval = 0.006).

Quality of life related to PD as measured with the PDQ39-SI improved by 2.91±2.25 (pval = 0.005),
mainly driven by an improvement of quality of life for activities of daily living. The other subdomains
of the PDQ39 did not improve significantly. No significant change in mood (BDI), motivation (Starkstein
Apathy Scale), overall cognition (MoCA), and dopaminergic medication (levodopa equivalent daily
dose [LEDD]) was observed.

351 During dose-escalation, one patient reported a general effect of well-being and more energy that 352 lasted longer with increasing doses up to 1 week with GM1 720 mg. All patients reported mild to 353 moderate reduction of the previously perceived beneficial effects during the month between the last 354 infusion and the follow-up safety assessment. No lasting worsening beyond baseline was observed after one month's withdrawal of TLN. In the first three patients, total GM1 dose was resumed at 720 355 356 mg weekly after a month's pause following dose escalation; within one or two infusions the previous 357 level of well-being was re-attained. All patients emphatically requested to prolong TLN treatment at 358 the end of the study. An amendment for study prolongation was therefore submitted.

Assessment (n=11)	Baseline Mean±SD	Follow-up Mean±SD	Mean Change from Baseline Mean±SD	Baseline Median (min,max)	Follow-up Median (min,max)	Median change from baseline (min,max)	p-value (Wilcoxon)
MDS-UPDRS 1	7.82±4.92	5.91±4.11	-1.91±2.66	6.00 (2.00, 17.00)	7.00 (1.00, 13.00)	-2.00 (-5.00, 4.00)	0.057
MDS-UPDRS 2 best	8.00±6.91	5.18±7.22	-2.82±3.34	7.00 (0.00, 23.00)	3.00 (0.00, 21.00)	-2.00 (-9.00, 1.00)	0.017
MDS-UPDRS 2 worst	8.18±7.36	6.45±7.55	-1.73±3.98	7.00 (0.00, 25.00)	3.00 (0.00, 22.00)	-1.00 (-9.00, 6.00)	0.122
MDS-UPDRS 3 off	16.09±8.32	9.36±5.55	-6.73±7.16	17.00 (6.00, 36.00)	8.00 (1.00, 19.00)	-7.00 (-24.00, 2.00)	0.009
MDS-UPDRS 3 on	6.45±3.42	6.00±4.98	-0.45±3.42	5.00 (2.00, 12.00)	5.00 (1.00, 17.00)	-1.00 (-6.00, 5.00)	0.561
MDS-UPDRS 4	2.18±3.52	1.45±3.30	-0.73±1.10	1.00 (0.00, 12.00)	0.00 (0.00, 11.00)	0.00 (-3.00, 0.00	0.098
MDS-UPDRS total	34.27±21.79	23.18±16.86	- 11.09 ±10.47	29.00 (10.00, 90.00)	16.00 (5.00, 58.00)	-5.00 (-32.00, 0.00)	0.006
NMS-Quest	8.64±3.98	4.36±3.29	-4.27±3.29	8.00 (2.00, 15.00)	5.00 (1.00, 10.00)	-5.00 (-9.00, 0.00)	0.009
MoCA	28.18±1.33	27.45±2.16	-0.73±2.00	29.00 (26.00, 30.00)	28.00 (24.00, 30.00)	-1.00 (-4.00, 3.00)	0.255
PDQ39-Summary index	20.11±8.32	17.21±7.02	-2.91±2.25	16.25 (9.69, 33.91)	15.52 (9.17, 28.65)	-2.92 (-6.30, 1.77)	0.005

Table 6. Motor signs and non-motor symptoms, quality of life, and LEDD for the 11 patients.

PDQ39 activites of daily	15.91±13.41	8.71±9.21	-7.20±8.35	12.50 (0.00, 33.33)	4.17 (0.00, 25.00)	-4.17 (-20.83, 4.17)	0.035
PDQ39 bodily	34.85±17.41	30.30±18.36	-4.55±12.00	41.67 (0.00, 58.33)	33.33 (0.00, 58.33)	0.00 (-25.00, 16.66)	0.309
PDQ39 cognitive	22.73±18.39	19.32±13.24	-3.41±15.65	25.00 (0.00, 56.25)	18.75 (0.00, 50.00)	0.00 (-37.50, 12.50)	0.518
PDQ39 communication	18.18±22.92	21.97±27.46	3.79±12.00	8.33 (0.00, 66.67)	16.67 (0.00, 75.00)	0.00 (-16.67, 25.00)	0.339
PDQ39 mobility	12.05±7.40	8.86±7.93	-3.18±6.90	12.50 (2.50, 22.50)	5.00 (0.00, 22.50)	-2.50 (-15.00, 10.00)	0.066
PDQ39 social support	12.12±10.78	7.58±6.93	-4.55±8.63	8.33 (0.00, 33.33)	8.33 (0.00, 16.67)	0.00 (-25.00, 8.34)	0.203
PDQ39 stigma	20.45±17.48	21.59±20.98	1.14±6.14	12.50 (0.00, 50.00)	18.75 (0.00, 62.50)	0.00 (-6.25, 12.50)	0.588
PDQ39 emotional	24.62±17.33	19.32±12.54	-5.30±12.37	20.83 (0.00, 58.33)	16.67 (8.33, 41.67)	-4.17 (-29.16, 8.33	0.332
Epworth Sleepiness	7.73±5.20	7.82±4.85	0.09±3.96	6.00 (3.00, 19.00)	8.00 (1.00, 16.00)	0.00 (-7.00, 8.00)	>0.999
Beck Depression	10.55±4.27	9.27±5.20	-1.27±3.77	10.00 (4.00, 19.00)	8.00 (3.00, 21.00)	0.00 (-7.00, 4.00)	0.257
Starkstein Apathy Scale	11.64±4.90	12.00±4.29	0.36±2.98	12.00 (3.00, 19.00)	10.00 (4.00, 18.00)	1.00 (-4.00, 6.00)	0.822
LEDD	745.91±330.5	754.09±327.	8.18±23.69	750.00 (340.0	0, 750.00 (340.00,	0.00 (-10.00, 75.00)	0.423

361 **Discussion**

362 In this open phase I clinical safety trial 12 PD patients received weekly infusions with liposomal GM1 363 for 8 to 22 weeks. Tolerability was overall very good with no or mild unspecific adverse reactions to 364 the infusion. Some fatigue and dizziness occurred repeatedly in some but not all patients after the infusion and lasted for a few hours, so a causal link to TLN seems probable. However, there were acute 365 366 infusion reactions in 7 of the 12 patients at the 2nd, 3rd, or 4th exposure to TLN. The intensity was 367 mild to moderate and in one case severe leading to exclusion from further study treatment. These 368 reactions were most pronounced at second exposure, consisted mostly of neck and lumbar back pain, 369 and swiftly abated within minutes after TLN infusions were paused. An allergic IgE-mediated 370 anaphylactic reaction seems highly unlikely as re-exposure did not lead to reappearance of the 371 symptoms but to habituation. Moreover, tryptase was measured before and after an acute infusion 372 reaction with urticaria at the 3rd exposure in one patient and remained stable in the normal range. 373 We therefore considered a complement activation related pseudo-allergy (CARPA) to the liposome as 374 an explanation for the acute infusion reactions (23). However, CARPAs typically occur with the first 375 exposure and habituate thereafter, whereas in our patients the first exposure was unproblematic in 376 all 12 patients. Moreover, the clinical manifestation of CARPAs is not typically reported as back pain 377 which was the main manifestation in our patients. The occurrence of the acute infusion reaction only at the 2nd administration is suggestive of a sensitization to TLN, however, the unproblematic tolerance 378 379 of re-exposure makes autoantibodies to GM1 an unlikely explanation, especially as anti-GM1-IgM 380 levels remained normal throughout the study in these patients and did not increase. Although we 381 cannot explain the mechanism of the observed acute infusion reactions, slowing the infusion rate and 382 possibly progressively increasing doses over the first weeks of treatment with TLN seem to prevent 383 such reactions. Free GM1 has been administered intravenously for over three decades in several 384 neurological disorders for up to 2500 mg/d without observing acute infusion reactions (24). In 385 particular in the randomized placebo-controlled trial with subcutaneous free GM1 patients received

386 a single intravenous loading dose of 1000 mg GM1. The subsequent subcutaneous administration of 387 GM1 in this study was a route of administration with a much higher risk of triggering an allergic 388 reaction to GM1 than intravenous administration, but no allergic side effects were reported. 389 Therefore, we suspect the acute infusion reactions in our patients to be related to the liposomal 390 carrier of GM1. Further analyses of possible mechanisms for an acute reaction to TLN are ongoing 391 outside of this trial. Other safety assessments of TLN will include lab analyses of blood samples drawn 392 after potential further acute infusion reactions to assess tryptase, thromboxanes, complement 393 factors, activation of factor XII, and measures of basophile activation. However, we try to completely 394 avoid further adverse reactions of this nature by gradually increasing the dose of TLN over the first 395 weeks and by starting the speed of infusion at a very low rate and ramping up as tolerated, especially 396 for the 2nd and 3rd administration of TLN.

397 Although hyperlipidemia was present in some of our patients already at baseline, there was no 398 consistent increase of lipid levels throughout the trial as had been observed with the administration 399 of very high doses of free GM1 previously (24). Hyperlipidemia was likely overestimated in our patients 400 as blood was drawn in non-fasting conditions. However, HDL cholesterol was slightly but significantly lowered under TLN treatment which may consist in a vascular risk factor. There were no adverse 401 402 events related to atherosclerosis in this study, but the observation period was very short. For more 403 conclusive results, lipid levels must be assessed systematically and under standardized fasting 404 conditions in patients treated with TLN in future studies.

Although this is an uncontrolled phase I safety trial, we gathered exploratory data on the possible therapeutic effects of TLN as a basis for power calculations for a therapeutic trial. In terms of PD symptoms, all patients felt stable or better over the study period. Improvements of sleep quality, motivation, sense of smell, and overall energy were reported, gradually occurring over several weeks. The drug withdrawal for the second levodopa challenge test was much better tolerated by most patients than the first, and several participants reported that accidental omission of a dose of

411 levodopa was much less perceived than before the treatment with TLN. These encouraging 412 observations are reflected in an improvement of non-motor (MDS-UPDRS-1, NMS-Quest) and motor 413 aspects of experiences of daily living (MDS-UPDRS-2), and of parkinsonian motor signs (MDS-UPDRS-414 3) resulting in an improvement of disease-related quality of life (PDQ-39). The observed improvements 415 of the MDS-UPDRS-1 and MDS-UPDRS-2 of 1.91 and 2.82 points are below the minimal clinically 416 relevant difference of 2.64 and 3.05 for these scales (25). However, for the motor signs, the minimal 417 clinical improvement on the MDS-UPDRS-3 has been suggested at 3.5 points (26), and our patients 418 improved by 6.73 points. The minimal clinically relevant improvement on the MDS-UPDRS total score 419 has been estimated at 7.1 points (27), whereas our patients improved by 11.09 points. However, for 420 disease-related quality of life measured by the PDQ-39 the minimal clinically important improvement 421 of 4.72% (28) is not reached with 2.9% observed in our patients. These exploratory observations are 422 encouraging, especially as they uniformly point towards an improvement on different established 423 scales despite a very small number of patients. The observed improvements occurred gradually over 424 the study period. No immediate effect on motor signs was found in the ratings before and after TLN 425 infusions. A rapid symptomatic beneficial effect of TLN on parkinsonian signs and symptoms is 426 therefore most unlikely. Moreover, as there was no selection of patients based on minimum disease 427 severity, regression to the mean is unlikely to explain the observed improvement in this study. If there 428 is indeed a therapeutic effect of TLN, either a long-term symptomatic effect or a disease-modifying 429 effect seems possible. As the annual progression of PD in its natural course has been estimated at 5.05 430 points in the untreated and 2.13 points in the treated condition for the sum of the MDS-UPDRS-2 and 431 -3 (29), the observed improvement among our patients may point to a long-term symptomatic or even 432 a neurorestorative effect. Indeed, GM1 can stabilize alpha-synuclein (7) and has a neurorestorative 433 effect on neurons in animal models of PD (30). Suffering neurons in patients with PD may therefore 434 be rescued by GM1 treatment, and a liposomal formulation may be an effective approach to deliver 435 GM1 into the central and peripheral nervous system. This may explain a gradual and long-lasting 436 reparative effect of TLN despite its short plasma half-life of 12.6h. However, all this remains

- 437 speculative at present. As this trial is not designed to show a therapeutic effect of TLN given the open
- 438 design without placebo control, a placebo effect may explain the observed improvements. An
- 439 adequately powered randomized placebo-controlled trial of TLN in PD is needed to further explore
- this promising new treatment.

441 Acknowledgments

442 MedDRA[®] trademark is registered by ICH.

443 References

444 445 446 447	1.	Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord [Internet]. 2015 Oct 1 [cited 2023 Jun 20];30(12):1591–601. Available from: https://pubmed.ncbi.nlm.nih.gov/26474316/
448 449 450 451	2.	Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E, et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol [Internet]. 2021 Jun 1 [cited 2023 Jun 20];17(6):349–61. Available from: https://pubmed.ncbi.nlm.nih.gov/33879872/
452 453 454 455	3.	Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging [Internet]. 2003 Mar [cited 2023 Jun 20];24(2):197–211. Available from: https://pubmed.ncbi.nlm.nih.gov/12498954/
456 457 458	4.	Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD. Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol [Internet]. 2017 Feb 13 [cited 2023 Jun 20];8(FEB). Available from: https://pubmed.ncbi.nlm.nih.gov/28243222/
459 460 461 462	5.	McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. J Parkinsons Dis [Internet]. 2022 [cited 2023 Jun 20];12(4):1073–82. Available from: https://pubmed.ncbi.nlm.nih.gov/35527571/
463 464 465 466	6.	te Vruchte D, Sturchio A, Priestman DA, Tsitsi P, Hertz E, Andréasson M, et al. Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels. Mov Disord [Internet]. 2022 Oct 1 [cited 2023 Jun 20];37(10):2129–34. Available from: https://pubmed.ncbi.nlm.nih.gov/35876461/
467 468 469	7.	Sonnino S. The relationship between depletion of brain GM1 ganglioside and Parkinson's disease. FEBS Open Bio [Internet]. 2023 [cited 2023 Jun 20]; Available from: https://pubmed.ncbi.nlm.nih.gov/36638010/
470 471 472	8.	Chowdhury S, Ledeen R. The Key Role of GM1 Ganglioside in Parkinson's Disease. Biomolecules [Internet]. 2022 Jan 21 [cited 2023 Jun 20];12(2). Available from: https://pubmed.ncbi.nlm.nih.gov/35204675/
473 474 475 476	9.	Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science [Internet]. 1992 [cited 2023 Jun 20];256(5058):843–6. Available from: https://pubmed.ncbi.nlm.nih.gov/1350379/
477 478 479 480	10.	Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W, et al. A Randomized, Controlled, Delayed Start Trial of GM1 Ganglioside in Treated Parkinson's Disease Patients Jay. J Neurol Sci [Internet]. 2013;324(1–2):140–8. Available from: http://dx.doi.org/10.1016/j.jns.2012.10.024
481 482	11.	Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease

483 484		patients. J Neurol Sci [Internet]. 2013 Jan 15 [cited 2023 Jun 20];324(1–2):140–8. Available from: https://pubmed.ncbi.nlm.nih.gov/23199590/
485 486 487 488	12.	Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry [Internet]. 1992 [cited 2023 Jun 20];55(3):181–4. Available from: https://pubmed.ncbi.nlm.nih.gov/1564476/
489 490 491	13.	Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology [Internet]. 1967 [cited 2023 Jun 20];17(5):427–42. Available from: https://pubmed.ncbi.nlm.nih.gov/6067254/
492 493 494 495	14.	Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc [Internet]. 2005 [cited 2023 Jun 20];53(4):695–9. Available from: https://pubmed.ncbi.nlm.nih.gov/15817019/
496 497 498 499 500	15.	Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord [Internet]. 2008 Nov 15 [cited 2023 Jun 20];23(15):2129–70. Available from: https://pubmed.ncbi.nlm.nih.gov/19025984/
501 502 503	16.	Nyholm D, Jost WH. An updated calculator for determining levodopa-equivalent dose. Neurol Res Pract [Internet]. 2021 Dec 1 [cited 2023 Jun 20];3(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34689840/
504 505 506 507 508	17.	Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord [Internet]. 2006 [cited 2023 Jun 20];21(7):916–23. Available from: https://pubmed.ncbi.nlm.nih.gov/16547944/
509 510 511 512	18.	Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res [Internet]. 1995 Jun [cited 2023 Jun 20];4(3):241–8. Available from: https://pubmed.ncbi.nlm.nih.gov/7613534/
513 514 515	19.	Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep [Internet]. 1991 [cited 2023 Jun 20];14(6):540–5. Available from: https://pubmed.ncbi.nlm.nih.gov/1798888/
516 517 518 519	20.	Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc [Internet]. 2005 [cited 2023 Jun 20];53(4):695–9. Available from: https://pubmed.ncbi.nlm.nih.gov/15817019/
520 521 522	21.	Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry [Internet]. 1961 [cited 2023 Jun 20];4(6):561–71. Available from: https://pubmed.ncbi.nlm.nih.gov/13688369/
523 524	22.	Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J

poipt	ciary.
It is made available under a C	C-BY 4.0 International license.

525 526		Neuropsychiatry Clin Neurosci [Internet]. 1992 [cited 2023 Jun 20];4(2):134–9. Available from: https://pubmed.ncbi.nlm.nih.gov/1627973/
527 528 529 530	23.	Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol [Internet]. 2018 Dec 1 [cited 2023 Jun 20];13(12):1100–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30348955/
531 532 533	24.	Roberts JW, Hoeg JM, Maral Mouradian M, Linfante I, Chase TN. latrogenic hyperlipidaemia with GM1 ganglioside. Lancet [Internet]. 1993 Jul 10 [cited 2023 Jun 20];342(8863):115. Available from: https://pubmed.ncbi.nlm.nih.gov/8100881/
534 535 536 537 538	25.	Horváth K, Aschermann Z, Kovács M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale. Mov Disord [Internet]. 2017 May 1 [cited 2023 Jun 20];32(5):789–93. Available from: https://pubmed.ncbi.nlm.nih.gov/28218413/
539 540 541 542	26.	Horváth K, Aschermann Z, Ács P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord [Internet]. 2015 Dec 1 [cited 2023 Jun 20];21(12):1421–6. Available from: https://pubmed.ncbi.nlm.nih.gov/26578041/
543 544 545 546	27.	Makkos A, Kovács M, Aschermann Z, Harmat M, Janszky J, Karádi K, et al. Are the MDS-UPDRS-Based Composite Scores Clinically Applicable? Mov Disord [Internet]. 2018 May 1 [cited 2023 Jun 20];33(5):835–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29488318/
547 548 549 550	28.	Horváth K, Aschermann Z, Kovács M, Makkos A, Harmat M, Janszky J, et al. Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant? Neuroepidemiology [Internet]. 2017 Jun 1 [cited 2023 Jun 20];48(1–2):1–8. Available from: https://pubmed.ncbi.nlm.nih.gov/28161701/
551 552 553 554 555	29.	Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, et al. Large- scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol [Internet]. 2017 Nov 1 [cited 2023 Jun 20];16(11):908–16. Available from: https://pubmed.ncbi.nlm.nih.gov/28958801/
556 557 558 559	30.	Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease. Sci Rep [Internet]. 2019 Dec 1 [cited 2023 Jun 20];9(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31182727/
560		
561		

Supporting information 562

- S1 Checklist. Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) 563
- 564 statement checklist.
- 565
- 566 S2 Text. Clinical trial protocol.
- 567
- 568 **Appendix 1 Laboratory analysis list**
- 569 Sodium, potassium, calcium, phosphate, creatinine, urea, albumin, total protein, cystatin C, lactate
- dehydrogenase, ferritin, HbA1c, ALT, AST, total bilirubin, pancreatic amylase, alkaline phosphatase, 570
- 571 cholesterol (total, LDL, HDL), apolipoprotein B, differentiated red and white blood cell count,
- thrombocytes, ganglioside GM1 IgG antibodies 572

573 Appendix 2: Observed lab values and weekly change

Variable	Week	Median	Median change	p-value	Mean (SD)	Mean change
		(min,max)	from Baseline	(Wilcoxon)		from Baseline
			(min, max)			(SD)
Total	Baseline	5.81 (4.20, 6.27)	-	-	5.44 (0.71)	-
cholesterol	(week 1					
CHOICSLEIDI	assessment)	/				
(mmol/L)	Week 2	5.64 (3.79, 6.14)	-0.13 (-0.89, 0.40)	0.398	5.32 (0.84)	-0.12 (0.37)
(111101/ L)	Week 3	5.35 (3.83, 6.35)	-0.09 (-0.85, 0.69)	0.577	5.36 (0.89)	-0.08 (0.48)
	Week 4	5.15 (3.90, 6.62)	-0.34 (-1.44, 0.67)	0.147	5.13 (0.86)	-0.31 (0.59)
	Week 5	5.25 (3.80, 6.46)	-0.13 (-0.88, 0.54)	0.240	5.27 (0.90)	-0.18 (0.44)
	Week 6	5.56 (3.80, 6.18)	-0.25 (-0.66, 0.36)	0.056	5.23 (0.83)	-0.21 (0.32)
	Week 7	5.61 (3.85, 6.80)	-0.15 (-0.83, 0.88)	0.533	5.40 (0.92)	-0.05 (0.43)
	Week 8	5.78 (3.96, 6.58)	0.03 (-0.50, 0.61)	0.638	5.50 (0.89)	0.05 (0.34)
	Final	5.48 (4.05, 6.56)	0.10 (-0.41, 0.64)	0.700	5.50 (0.85)	0.05 (0.40)
	Assessment					
	Follow up	5.12 (4.01, 6.49)	-0.46 (-1.84, 0.92)	0.278	5.15 (0.78)	-0.30 (0.75)
LDL	Baseline	3.44 (2.46, 4.22)	-	-	3.35 (0.64)	-
cholesterol	(week 1					
010103(0101	assessment)					
(mmol/L)	Week 2	3.27 (2.00, 4.62)	-0.12 (-0.84, 0.69)	0.359	3.21 (0.87)	-0.14 (0.46)
(111110//L)	Week 3	3.20 (2.28, 4.74)	-0.17 (-0.62, 0.88)	0.898	3.40 (0.83)	0.05 (0.54)
	Week 4	3.10 (1.73, 4.54)	-0.35 (-0.95, 0.61)	0.147	3.09 (0.79)	-0.26 (0.52)
	Week 5	3.07 (1.90, 4.80)	-0.11 (-1.00, 0.87)	0.240	3.24 (0.90)	-0.11 (0.46)
	Week 6	3.28 (2.04, 4.12)	-0.11 (-0.50, 0.47)	0.413	3.26 (0.66)	-0.09 (0.31)
	Week 7	3.72 (1.95, 4.33)	0.01 (-0.95, 0.83)	0.898	3.36 (0.83)	0.01 (0.48)
	Week 8	3.50 (1.73, 4.41)	0.05 (-1.12, 0.61)	0.898	3.27 (0.89)	-0.08 (0.56)
	Final	3.72 (1.94, 4.57)	0.25 (-0.55, 0.89)	0.240	3.55 (0.75)	0.20 (0.51)
	Assessment					
	Follow up	2.90 (2.48, 4.52)	-0.20 (-1.25, 0.69)	0.824	3.25 (0.70)	-0.10 (0.55)
HDL	Baseline	1.22 (0.90, 2.76)	-	-	1.35 (0.50)	-
cholesterol	(week 1					
cholesteroi	assessment)					
(mmol/L)	Week 2	1.08 (0.72, 2.47)	-0.14 (-0.29, -0.05)	0.004	1.20 (0.45)	-0.15 (0.07)
	Week 3	1.13 (0.79, 2.59)	-0.16 (-0.27, -0.02)	<0.001	1.19 (0.49)	-0.16 (0.07)
	Week 4	1.05 (0.72, 2.23)	-0.18 (-0.53, -0.10)	<0.001	1.14 (0.40)	-0.21 (0.12)
	Week 5	1.09 (0.70, 2.24)	-0.18 (-0.52, -0.05)	<0.001	1.15 (0.40)	-0.20 (0.13)
	Week 6	1.04 (0.72, 2.20)	-0.18 (-0.56, -0.10)	0.004	1.11 (0.39)	-0.24 (0.15)
	Week 7	0.97 (0.72, 2.53)	-0.23 (-0.39, 0.00)	0.006	1.13 (0.50)	-0.22 (0.11)
	Week 8	1.13 (0.72, 2.52)	-0.18 (-0.36, 0.05)	0.005	1.18 (0.48)	-0.17 (0.10)
	Final	1.14 (0.76, 2.41)	-0.14 (-0.35, 0.09)	0.021	1.21 (0.44)	-0.13 (0.14)
	Assessment					
	Follow up	1.14 (0.77, 2.45)	-0.11 (-0.34, 0.05)	0.008	1.22 (0.44)	-0.13 (0.12)

Triglycerides	Baseline (week 1	1.54 (0.59, 2.71)	-	-	1.64 (0.71)	-
(mmol/L)	assessment)					
(1111101/ L)	Week 2	1.44 (0.82, 3.60)	0.37 (-0.81, 1.56)	0.123	2.00 (1.13)	0.35 (0.69)
	Week 3	1.77 (0.72, 2.90)	0.09 (-0.94, 1.10)	0.563	1.71 (0.75)	0.06 (0.58)
	Week 4	1.35 (0.64, 4.52)	0.05 (-0.60, 2.98)	0.625	1.99 (1.22)	0.35 (1.04)
	Week 5	1.89 (0.70, 3.03)	0.23 (-0.76, 1.29)	0.175	1.92 (0.79)	0.28 (0.62)
	Week 6	1.72 (0.82, 3.26)	0.08 (-0.17, 1.59)	0.130	1.92 (0.81)	0.28 (0.50)
	Week 7	2.05 (1.15, 4.85)	0.44 (-0.46, 2.14)	0.042	2.24 (1.11)	0.59 (0.80)
	Week 8	2.13 (0.78, 4.47)	0.31 (-0.62, 2.99)	0.102	2.29 (1.32)	0.65 (1.08)
	Final	1.45 (0.54, 2.98)	-0.18 (-1.38, 0.67)	0.765	1.61 (0.71)	-0.03 (0.59)
	Assessment					
	Follow up	1.12 (0.61, 2.95)	-0.20 (-1.62, 1.21)	0.320	1.49 (0.79)	-0.15 (0.69)
Apolipoprotein	Baseline	0.91 (0.71, 1.11)	-	-	0.94 (0.13)	0.00 (0.00)
D	(week 1					
D	assessment)					
(1)	Week 2	0.83 (0.66, 1.13)	0.02 (-0.25, 0.08)	>0.999	0.92 (0.17)	-0.02 (0.10)
(g/L)	Week 3	0.87 (0.70, 1.16)	0.02 (-0.21, 0.11)	0.638	0.94 (0.16)	0.01 (0.09)
	Week 4	0.88 (0.74, 1.20)	0.02 (-0.17, 0.09)	>0.999	0.93 (0.16)	-0.01 (0.09)
	Week 5	0.94 (0.72, 1.24)	0.02 (-0.19, 0.22)	0.126	0.97 (0.18)	0.03 (0.10)
	Week 6	0.96 (0.74, 1.18)	0.06 (-0.17, 0.15)	0.240	0.98 (0.16)	0.04 (0.10)
	Week 7	1.01 (0.74, 1.22)	0.08 (-0.17, 0.30)	0.036	1.02 (0.16)	0.08 (0.12)
	Week 8	1.08 (0.80, 1.32)	0.10 (-0.11, 0.27)	0.032	1.04 (0.17)	0.11 (0.13)
	Final	1.12 (0.88, 1.38)	0.14 (-0.03, 0.27)	0.008	1.07 (0.16)	0.14 (0.11)
	Assessment					
	Follow up	0.96 (0.79, 1.25)	0.04 (-0.13, 0.19)	0.168	0.98 (0.14)	0.05 (0.10)
Total/HDL	Baseline	4.42 (2.14, 5.15)	-	-	4.29 (0.84)	-
choloctorol	(week 1					
CHOIESIEIDI	assessment)					
(mmol/mmol)	Week 2	4.85 (2.49, 5.85)	0.50 (-0.57, 1.14)	0.024	4.72 (1.06)	0.43 (0.46)
	Week 3	5.28 (2.38, 5.96)	0.55 (-0.18, 1.54)	0.002	4.83 (1.02)	0.53 (0.41)
	Week 4	4.87 (2.59, 6.09)	0.39 (-0.20, 1.67)	0.010	4.78 (1.06)	0.48 (0.55)
	Week 5	5.05 (2.53, 6.15)	0.57 (-0.45, 1.43)	0.010	4.85 (1.06)	0.55 (0.53)
	Week 6	5.24 (2.64, 6.39)	0.49 (-0.11, 2.04)	0.002	4.99 (1.06)	0.70 (0.58)
	Week 7	5.35 (2.69, 6.73)	0.79 (0.21, 2.11)	<0.001	5.15 (1.05)	0.86 (0.49)
	Week 8	5.25 (2.54, 6.08)	0.54 (-0.01, 1.86)	0.002	4.99 (1.01)	0.70 (0.55)
	Final	4.99 (2.72, 6.13)	0.55 (-0.47, 1.51)	0.010	4.80 (0.96)	0.51 (0.55)
	Assessment	/				`` <i>`</i>
	Follow up	4.57 (2.23, 5.82)	0.08 (-0.36, 1.40)	0.365	4.52 (1.08)	0.22 (0.58)